|Meloxicam||Nonsteroidal anti-inflammatory drug (NSAID)|
Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery. It contains bupivacaine and meloxicam.
In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.
In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty in adults.
- "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.
- "Bupivacaine mixture with meloxicam". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03295721 for "Bunionectomy Study for Postoperative Analgesia (EPOCH 1)" at ClinicalTrials.gov
- Clinical trial number NCT03237481 for "Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)" at ClinicalTrials.gov
- Clinical trial number NCT03015532 for "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia" at ClinicalTrials.gov